Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque.
Marfella R, Prattichizzo F, Sardu C, Paolisso P, D'Onofrio N, Scisciola L, La Grotta R, Frigé C, Ferraraccio F, Panarese I, Fanelli M, Modugno P, Calafiore AM, Melchionna M, Sasso FC, Furbatto F, D'Andrea D, Siniscalchi M, Mauro C, Cesaro A, Calabrò P, Santulli G, Balestrieri ML, Barbato E, Ceriello A, Paolisso G. Marfella R, et al. Among authors: cesaro a. Atherosclerosis. 2023 Aug;378:117180. doi: 10.1016/j.atherosclerosis.2023.06.971. Epub 2023 Jun 29. Atherosclerosis. 2023. PMID: 37422356
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience.
Gragnano F, Natale F, Concilio C, Fimiani F, Cesaro A, Sperlongano S, Crisci M, Limongelli G, Calabrò R, Russo M, Golia E, Calabrò P. Gragnano F, et al. Among authors: cesaro a. J Cardiovasc Med (Hagerstown). 2018 Feb;19(2):75-77. doi: 10.2459/JCM.0000000000000611. J Cardiovasc Med (Hagerstown). 2018. PMID: 29251697 No abstract available.
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)".
Calabrò P, Gragnano F, Cesaro A. Calabrò P, et al. Among authors: cesaro a. Circulation. 2018 Jul 10;138(2):218-219. doi: 10.1161/CIRCULATIONAHA.117.033137. Circulation. 2018. PMID: 29986968 No abstract available.
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events.
Cesaro A, Moscarella E, Gragnano F, Perrotta R, Diana V, Pariggiano I, Concilio C, Alfieri A, Cesaro F, Mercone G, Falato S, Esposito A, Di Girolamo D, Limongelli G, Calabrò P. Cesaro A, et al. Among authors: cesaro f. Expert Rev Cardiovasc Ther. 2019 Jun;17(6):435-447. doi: 10.1080/14779072.2019.1627873. Expert Rev Cardiovasc Ther. 2019. PMID: 31213156 Review.
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry).
Calabrò P, Moscarella E, Gragnano F, Cesaro A, Pafundi PC, Patti G, Cavallari I, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Sasso FC, Pengo V, Gresele P, Marcucci R; START-ANTIPLATELET collaborators; Conte M, Fimiani F, Di Serafino L, Del Pinto M, Denas G, Pastori D, Eleonora C, Fierro T. Calabrò P, et al. Among authors: cesaro a. Am J Cardiol. 2019 Dec 1;124(11):1662-1668. doi: 10.1016/j.amjcard.2019.08.030. Epub 2019 Sep 6. Am J Cardiol. 2019. PMID: 31585697
282 results